Buy Like Buffett
Watchlist

Flagship explainer

How EVOFEM BIOSCIENCES, INC. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$20.2M · 100%Cost of revenue$4.6M · 23%Gross profit$15.6M · 77%Operating income$3.4M · 17%Income before tax$393000 · 2%Income tax$2000 · 0%Net income$391000 · 2%As of 2025-12-31 · 2 SEC filing sourcesBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$20.2M100%
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-009686 · filed Mar 11, 2026
Cost of revenue$4.6M23%
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-009686 · filed Mar 11, 2026
$15.6M77%
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-009686 · filed Mar 11, 2026
$3.4M17%
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-009686 · filed Mar 11, 2026
Income before tax$3930002%
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-009686 · filed Mar 11, 2026
Income tax$20000%
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-009686 · filed Mar 11, 2026
$3910002%
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-009686 · filed Mar 11, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001493152-26-009686 · filed Mar 11, 2026
· event Dec 31, 2025 · retrieved Oct 18, 2026 · annual-row source set
Embed this chart

View the full EVOFEM BIOSCIENCES, INC. analysis at Buy Like Buffett